Todd Franklin Watanabe
President, CEO & DirectorMr. Todd Franklin Watanabe, also known as Frank, M.A., serves as Director of Amunix Pharmaceuticals, Inc. since June 2021. He has been President of Arcutis Biotherapeutics, Inc. (Formerly known as Arcutis Inc.) since 2016, Chief Executive Officer since April 2017 and serves as its Director since 2017. Prior to joining Arcutis, he was Co-owner at Watanabe Ventures, LLC. He was co-founder and Chief Operating Officer of Kanan Therapeutics, a cardiovascular drug development company from December 2015 to February 2018, and before that, was Vice President of Strategy and Corporate Development at Kythera Biopharmaceuticals from October 2013 to November 2015. Mr. Watanabe was an executive at Amgen, Inc. from 2005 to 2013, where he was involved in the development of Repatha for hyperlipidemia and Aimovig for migraine and worked on the U.S. marketing of Enbrel in both dermatology and rheumatology. Previously, he was an executive with Eli Lilly and company, and an official in the U.S. Government. He was also a commissioned officer in the U.S. Navy Reserves. Mr. Watanabe earned his M.A. in National Security Studies, and his B.A. in International Relations, both at Georgetown University.
Positions
- Company NameArcutis Biotherapeutics, Inc.Stock CodeARQTPositionPresident, CEO & DirectorColleagues
- KRKeith R. LeonardIndependent Chairman of the Board
- BCBhaskar ChaudhuriCo-Founder & Director Emeritus
- LVLatha VairavanSenior VP & Chief Financial Officer
- MMMasaru MatsudaExecutive VP, Chief Legal Officer & Corporate Secretary
- PEPatrick E. BurnettExecutive VP & Chief Medical Officer
- TJTerrie J. CurranIndependent Director
- ADAmit D. MunshiIndependent Director
